North America myositis treatment market is projected to register a CAGR of 6.5% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
North America Myositis Treatment Market, By Type (Polymyositis, Dermatomyositis, Inclusion Body Myositis (IBM), Necrotizing Myopathy, Juvenile Myositis, Others), Treatment (Medication, Therapy, Supplements), End User (Hospitals, Therapy Centers, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of North America myositis treatment market are:
- High demand of disease specific treatment
- Rising geriatric population and emerging cases of inflammation
Market Players:
The key market players for North America myositis treatment market are listed below:
- ADMA Biologics, Inc.
- CSL Behring (a subsidiary of CSL)
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical USA Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- Pfizer Inc.
- Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila)
- Amneal Pharmaceuticals LLC
- Horizon Therapeutics plc
- Grifols, S.A.
- Kedrion Biopharma Inc. (a subsidiary of Kedrion S.p.A)
- Bio Products Laboratory Ltd.
- Halozyme, Inc.
- ORPHAZYME A/S
- Alzheon, Inc.
- Abcuro, Inc.
- Corbus Pharmaceuticals Holdings, Inc.
- Accord Healthcare
- Sandoz AG (a subsidiary of Novartis AG)
